IQVIA (NYSE:IQV) Price Target Cut to $240.00 by Analysts at JPMorgan Chase & Co.

IQVIA (NYSE:IQV) had its target price reduced by JPMorgan Chase & Co. from $279.00 to $240.00 in a research report released on Tuesday,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Other research analysts have also recently issued research reports about the stock. Truist Financial decreased their target price on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Barclays lowered their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Evercore ISI dropped their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. BTIG Research reduced their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Redburn Atlantic assumed coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $259.13.

IQVIA Stock Up 0.7 %

Shares of IQVIA stock opened at $219.17 on Tuesday. IQVIA has a twelve month low of $190.20 and a twelve month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The business’s 50 day simple moving average is $231.00 and its 200-day simple moving average is $229.31. The stock has a market capitalization of $39.78 billion, a price-to-earnings ratio of 28.76, a PEG ratio of 2.26 and a beta of 1.51.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IQV. Intech Investment Management LLC bought a new stake in IQVIA in the third quarter worth approximately $223,000. Citizens Financial Group Inc. RI lifted its stake in shares of IQVIA by 19.8% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 2,463 shares of the medical research company’s stock valued at $584,000 after purchasing an additional 407 shares during the last quarter. EULAV Asset Management boosted its holdings in IQVIA by 4.4% in the third quarter. EULAV Asset Management now owns 309,000 shares of the medical research company’s stock worth $73,224,000 after purchasing an additional 13,000 shares in the last quarter. Advisors Asset Management Inc. increased its position in IQVIA by 74.3% during the third quarter. Advisors Asset Management Inc. now owns 2,845 shares of the medical research company’s stock worth $674,000 after buying an additional 1,213 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in IQVIA during the third quarter valued at about $6,059,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.